News | October 30, 2008

Medtronic to Launch Coronary Stents, Balloon Catheters on Rapid Exchange in U.S.

October 30, 2008 - Medtronic Inc. said today it plans to launch its portfolio of angioplasty products in the U.S. on the rapid exchange (RX) delivery system, including the Endeavor drug-eluting stent (DES), the Driver and MicroDriver bare-metal stents, and the NC (non-compliant) Sprinter balloon catheter systems.

Used in angioplasty procedures to treat coronary artery disease, RX is a short-, single-wire delivery system that can be used by one operator. It is the preferred delivery system of about three-quarters of U.S. interventional cardiologists, the company said. Medtronic anticipates that access to RX will increase usage of its angioplasty products in the United States.

“RX is a prescription for greater success in cardiac catheterization laboratories nationwide going forward,” said Sean Salmon, vice president and general manager of the coronary and peripheral vascular business at Medtronic. “Delivering the Endeavor stent on RX makes our flagship DES even more deliverable. Given the popularity of RX among physicians, patients with coronary artery disease across the country will soon be much more likely to receive the Endeavor stent, which has demonstrated both long-term safety and durable efficacy in extensive clinical research.”

Metronic believes offering RX will substantially boost its U.S. stent and balloon catheter sales, since its competitors already offer stents and balloons that use the more popular delivery system.

Abbott’s patent on its rapid exchange (RX) delivery system was supposed to expire Oct. 29. However, Abbott filed for a one-year patent extension, which was temporarily granted Oct. 17 by the U.S. Patent and Trademark Office. A decision is still pending on Abbott’s request to extend the patent until 2011 to account for time it took to develop and get FDA approval for its Xience stent.

For more information: www.medtronic.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Philips Announces Relaunch of Pioneer Plus IVUS-Guided Catheter
News | Chronic Total Occlusion (CTO)| June 28, 2017
June 28, 2017 — Royal Philips recently announced the relaunch of its Pioneer Plus...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Overlay Init